Does Rallies show 13F holders for DYN?

Yes. Rallies tracks hedge fund and 13F ownership data for DYN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DYN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DYN. It does not provide personalized investment advice.

DYN (Dyne Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Dyne Therapeutics, Inc. Common Stock (DYN) is a publicly traded Healthcare sector company. As of May 20, 2026, DYN trades at $16.57 with a market cap of $2.73B and a P/E ratio of -4.65. DYN moved +4.59% today. Year to date, DYN is -13.95%; over the trailing twelve months it is +36.54%. Its 52-week range spans $6.36 to $36.09. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces DYN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DYN stock?

Hedge funds tracked by Rallies that own DYN include Orbimed Advisors, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Dyne Therapeutics, Inc. Common Stock.

DYN Key Metrics

Key financial metrics for DYN
Metric	Value
Price	$16.57
Market Cap	$2.73B
P/E Ratio	-4.65
EPS	$-3.47
Dividend Yield	0.00%
52-Week High	$36.09
52-Week Low	$6.36
Volume	362.68K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-446.21M
Gross Margin	0.00%

Top Hedge Funds Holding DYN

Orbimed Advisors holds 2.92M shares of DYN, changed +32.50% as of Mar 31, 2026.
Mangrove Partners holds 47.93K shares of DYN, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 10.00K shares of DYN, changed +0.00% as of Mar 31, 2026.

Latest DYN News

Dyne Therapeutics Launches 72-Week Phase 3 FORZETTO Trial in 90 Duchenne Muscular Dystrophy Patients — May 20, 2026
Dyne Posts 9.48% Dystrophin Increase, On Track for Q2 2026 BLA Submission — May 11, 2026
Dyne Therapeutics FORCE Platform Achieves 75% MAPT RNA Knockdown in NHP — Apr 27, 2026
Dyne to Present DELIVER, ACHIEVE Data at AMCP, Eyes 2027 DMD and 2028 DM1 Launch — Apr 1, 2026
Dyne Therapeutics Achieves 5.46% Dystrophin Expression, Holds $1.1B Cash for Q2 BLA Plan — Mar 2, 2026

Recent DYN Insider Trades

Friedl-Naderer Johanna sold 228 (~$4.19K) on May 13, 2026.
Kerr Douglas sold 1.56K (~$28.72K) on May 13, 2026.
Lucera Erick sold 1.45K (~$26.59K) on May 13, 2026.

DYN Analyst Consensus

11 analysts cover DYN: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.

Common questions about DYN

Who owns DYN stock?: Hedge funds tracked by Rallies that own DYN include Orbimed Advisors, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Dyne Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for DYN?: Yes. Rallies tracks hedge fund and 13F ownership data for DYN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DYN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DYN. It does not provide personalized investment advice.